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Maturity-onset diabetes of the young 1 (MODY1) is amonogenic diabetes condition caused by hetero-
zygous HNF4A mutations. We investigate how HNF4A haploinsufficiency from a MODY1/HNF4A
mutation influences the development of foregut-derived liver and pancreatic cells through differenti-
ation of human induced pluripotent stem cells from a MODY1 family down the foregut lineage. In
MODY1-derived hepatopancreatic progenitors, which expressed reduced HNF4A levels and mislocal-
ized HNF4A, foregut genes were downregulated, whereas hindgut-specifyingHOX genes were upre-
gulated. MODY1-derived hepatocyte-like cells were found to exhibit altered morphology. Hepatic
and b cell gene signatures were also perturbed in MODY1-derived hepatocyte-like and b-like cells,
respectively. As mutant HNF4A (p.Ile271fs) did not undergo complete nonsense-mediated decay or
exert dominant negativity, HNF4A-mediated loss of function is likely due to impaired transcriptional
activation of target genes. Our results suggest that in MODY1, liver and pancreas development is
perturbed early on, contributing to altered hepatic proteins and b cell defects in patients.
INTRODUCTION
Maturity-onset diabetes of the young 1 (MODY1) is an autosomal dominant monogenic diabetes condition
typically manifesting before the age of 25 years. This condition is caused by inactivating mutations in the
hepatocyte nuclear factor 4A (HNF4A) gene (Yamagata et al., 1996) and is characterized by defects in
glucose-stimulated insulin secretion (GSIS) from the pancreatic b cells (Byrne et al., 1995). Owing to the
inaccessibility of human pancreatic tissue, rodent models have traditionally been used to study the molec-
ular mechanisms underlying MODY1. Unfortunately, conditional knockout of Hnf4a in mouse pancreatic b
cells did not result in a diabetic phenotype, although GSIS is impaired (Boj et al., 2010; Gupta et al., 2005;
Miura et al., 2006). More importantly, Hnf4a+/- mice exhibit normal glucose tolerance (Stoffel and Duncan,
1997), indicating that rodent models do not accurately recapitulate the MODY1 phenotype in humans.
Human induced pluripotent stem cell (hiPSC)-based disease modeling strategies (Teo et al., 2013a) there-
fore provide opportunities to investigate the impact of MODY1/HNF4A mutation on the development of
the foregut lineage in humans. In particular, the ventral foregut endoderm gives rise to progenitors that
subsequently form the liver, whose development and function is heavily dependent on regulation by
HNF4A, or the pancreatic b cells, which are known to be implicated in MODY1 pathophysiology.
HNF4A is a member of the steroid hormone receptor superfamily and functions as a transcription factor
upon homodimerization (Sladek et al., 1990). Its expression is regulated by either the P1 (proximal) or P2
(distal) promoter. The usage of alternate promoters and presence of alternative splicing results in up to
12 known HNF4A isoforms that are expressed in a developmental stage- and tissue-specific manner (Eeck-
houte et al., 2003a; Harries et al., 2008; Huang et al., 2009; Jiang et al., 2003; Tanaka et al., 2006). Therefore
HNF4A expression is dynamically regulated to ensure proper formation and function of multiple organs, in
particular, the liver and pancreas (Lau et al., 2018), which are the tissues we focus on in our study.
Knockout of Hnf4a in mice is dispensable for early development of the liver, whereas it is required for
driving hepatic specification at later stages and in maintaining proper liver function (Li et al., 2000). In an
early human pluripotent stem cell differentiation study, HNF4A was found to be necessary for establishing
the hepatic gene regulatory network and induction of hepatic cell fate (DeLaForest et al., 2011). This192 iScience 16, 192–205, June 28, 2019 ª 2019 The Author(s).
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Figure 1. HNF4A Mutation (p.Ile271fs) Causes Impaired Foregut/Early Hepatopancreatic Progenitor (HPP)
Development
(A) MODY1 family node showing non-diabetic control-hiPSCs (iN904-13 and iN904-7) and MODY1-hiPSCs (iN904-2 and
iN904-1).
(B) p.Ile271fs mutation results in C-terminally truncated HNF4A that lacks part of the ligand-binding domain (LBD) and the
entire F repressor domain (not drawn to scale).
(C) The 17-day differentiation protocol for generating foregut endoderm and HPPs.
(D) qPCR analysis of HNF4A expression during HPP differentiation.
(E) qPCR analyses ofHNF4A transcripts and foregut endodermmarkers such asHHEX,HNF1B, PDX1,GATA4, and RFX6 in
control and MODY1-HPPs.
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Figure 1. Continued
(F) Immunofluorescent confocal images showing the localization of HNF4A protein in control and MODY1-HPPs, based
on antibodies targeting the N- or C-terminal regions of HNF4A. Blue, DAPI; green, HNF4A; scale bars, 50 mm. White
arrows point to the nuclear or cytoplasmic localization signal of HNF4A. Confocal images were acquired using similar scan
settings across samples.
Data are represented as mean G SD of n = 3; representative of three independent experiments. *p < 0.05 versus D0 or
control samples by Student’s t test. See also Figures S1 and S2.correlates with the observation that patients with an inactivatingHNF4Amutation exhibit alterations in liver
function (Gardner and Tai, 2012; Pearson et al., 2005; Shih et al., 2000). In addition to the liver, Hnf4a is also
expressed in the maturing pancreas in mice and is largely confined to the developing islet and acinar cells
(Nammo et al., 2008). A recent study showed that MODY1/HNF4Amutation does not prevent formation of
INS+ cells from in vitro differentiations (Vethe et al., 2017). Nonetheless, the molecular and transcriptional
impacts of heterozygous HNF4A mutation on early foregut endoderm, liver, and pancreas development
leading to disease onset in humans remain largely unexplored.
We hypothesized that the MODY1/HNF4A mutation affects early human foregut development that can
potentially lead to both liver and pancreas developmental defects. To circumvent the lack of access to
human tissues during early development, we generated hiPSCs from members of a MODY1 family (with
and without heterozygous HNF4Amutation) and differentiated them into hepatopancreatic foregut endo-
derm (henceforth termed hepatopancreatic progenitors [HPPs]), as well as hepatic and pancreatic b-like
cells using independent, established protocols. Our data indicate that HNF4A haploinsufficiency, as a
result of a loss-of-function MODY1 mutation, affects early human foregut development and that this defi-
ciency is propagated to both hepatic and pancreatic cell fates. Our human disease model provides a plat-
form for investigating why patients with MODY1 have specific hepatic and b cell developmental defects.RESULTS
Establishing a MODY1 Disease Model Using Patient-Derived iPSCs
We previously reported the recruitment of two members of a MODY1 family harboring a heterozygous
p.Ile271fs mutation in HNF4A (Figure 1A) (Teo et al., 2013b) resulting in premature truncation of the protein
(Figure 1B). To facilitate rigorous and comprehensive hiPSC-basedMODY1 diseasemodeling, we recruited
more members of the same family and rederived a total of nine hiPSC lines composed of MODY1-hiPSCs
from two patients (iN904-2 and iN904-1A/B/C) and control-hiPSCs from two non-diabetic family members
(iN904-13A/B and iN904-7A/B/C) (Figures 1A and S1). Using a previously published 17-day foregut endo-
derm differentiation protocol, we observed thatHNF4A expression peaked at day 14 (D14) (Figures 1C and
1D) (Teo et al., 2015b, 2016), and that 70% of D14 HPPs were HNF4A+ (Figure S2A), thereby providing a
suitable model for studying HNF4A gene function and disease mechanisms underlying MODY1.HNF4A Mutation (p.Ile271fs) Causes Impaired Foregut/Early HPP Development
To elucidate the effects of the p.Ile271fs mutation, we simultaneously differentiated control- and MODY1-
hiPSCs into HPPs. Both control- and MODY1-hiPSCs were able to differentiate into definitive endoderm
cells at day 3 of differentiation (Figure S2B). At D14 of differentiation, although we observed no obvious
morphological differences between control- and MODY1-HPPs (Figure S2C), the MODY1-HPPs expressed
significantly lower levels of totalHNF4A (Figure 1E). In fact, wild-type (WT) HNF4A protein was expressed at
markedly lower levels in MODY1-HPPs based on protein expression data despite the presence of one copy
of the WT allele at HNF4A (Figure S2D). To determine if P1- or P2-driven HNF4A transcripts were affected,
we carried out isoform-specific qPCR analyses and showed that both P1- and P2-driven forms ofHNF4A are
potentially affected in the D14 HPPs (Figure S2E).
We further detected lower levels of foregut endoderm genes HHEX, HNF1B, PDX1, GATA4, and RFX6 in
the MODY1-HPPs, whereas no differences were observed for other pancreas-related genes SOX9 or
MNX1 (Figure 1E), reflecting a downregulation of specific gene targets ofHNF4A affected by the p.Ile271fs
mutation rather than a global downregulation of pancreatic developmental genes. Downregulation of
PDX1 andGATA4 was confirmed at protein level by immunofluorescence staining (Figure S2F). Subsequent
immunofluorescence analyses additionally revealed that HNF4A protein is largely sequestered in the cyto-
plasm of the MODY1-HPPs as opposed to the predominant nuclear localization observed in control-HPPs194 iScience 16, 192–205, June 28, 2019
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Figure 2. RNA Sequencing Analyses Reveal Global Transcriptional Changes Induced by the HNF4A Mutation in MODY1-HPPs at D14
(A–C) (A) Analysis of downregulated genes via the KEGG pathway. Heatmap analyses of (B) pancreas-related and (C) liver-related genes that are
downregulated with fold change (FC) > 1.5, p < 0.05.
(D) Heatmap analyses of numerous caudal HOX genes involved in hindgut specification that are upregulated with FC > 1.5, p < 0.05. Colors in the heatmap
depict gene expression in units of SD from the mean across all samples (upregulation in red, downregulation in blue). Controls indicated as 13A, 13B, 7A, 7B,
and 7C; MODY1 indicated as 2, 1A–1C.
(E) qPCR analyses of caudal HOX gene expression in control and MODY1-HPPs.
Data are represented as meanG SD of n = 3, representative of four independent experiments. *p < 0.05 versus control samples by Student’s t test. See also
Figure S3 and Table S1.(Figure 1F). Mislocalization of the HNF4A protein could further account for the loss of its function as a
transcription factor.RNA Sequencing Analyses Reveal Downregulation of Pancreas- and Liver-Related Genes and
Upregulation of Caudal HOX Genes
To thoroughly evaluate the genome-wide effects of theMODY1mutation on foregut development, we per-
formed RNA sequencing analyses on control andMODY1-hiPSC-derived D14 HPPs. Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway analyses revealed that genes involved in MODY and numerous liver
functions were significantly downregulated (Figure 2A), consistent with the known functions of HNF4A
target genes (Bolotin et al., 2010; Odomet al., 2004). The affected genes were involved in processes related
to steroid metabolism and lipoprotein and sterol binding and transport (Figure S3A), providing clues to the
role of HNF4A target genes. On the other hand, genes involved in DNA binding, transcription factor, and
channel activity were upregulated, possibly due to compensatory regulatory mechanisms (Figure S3B).
Heatmap analyses revealed that a subset of pancreas-related genes was downregulated in MODY1-HPPs
(fold change [FC] > 1.5; p < 0.05) (Figure 2B), including PDX1, the FOXA gene family,GATA4, RFX6,HNF1B,
KRT19, and SOX17. In addition, numerous hepatic genes such as the apolipoprotein (APO) genes, AFP,
TTR, and HHEX were also downregulated in the MODY1-HPPs (Figure 2C), consistent with findings from
Hnf4a/ mice (Li et al., 2000). In contrast, we were intrigued to observe an upregulation of numerous
caudal HOX genes including HOXA10, HOXC11, HOXC12, HOXD11, HOXD12, and HOXD13 in the
MODY1-HPPs (Figures 2D, 2E, and S3C). Although some of the changes were modest, likely due to the
fact that the HPP protocol is suited for foregut, but not hindgut, differentiation, the trend toward increased
levels of hindgut markers suggests a potential switch away from foregut specification. Indeed, these caudal
HOX genes are typically upregulated only in differentiation conditions favorable for hindgut formation
(high fibroblast growth factor 2 concentration) (Ameri et al., 2010) in which hindgut marker CDX2 is upre-
gulated, but not foregut marker HNF4A (Figure S3D). The loss of the repressor domain in HNF4A owing to
the p.Ile271fs-truncating mutation may account for this ‘‘derepression’’ phenomenon.MODY1-Mediated Loss of HNF4A Transcriptional Function Affects Subsequent Hepatic and
Pancreatic Development Signatures
Following theHNF4A loss-of-function observations in the HPPs, which are representative of a progenitor stage,
we next investigated impacts on subsequent tissue development. We used established differentiation proto-
cols that aimed to direct the differentiation of the hiPSCs into hepatocytes or pancreatic b-like cells (Hannan
et al., 2013; Pagliuca et al., 2014), as these aremore representative of the liver and b cell differentiation process.
First, time course differentiation of control-hiPSCs into hepatocyte-like cells (Hannan et al., 2013) revealed that
HNF4A expression peaked on day 8 (D8), when 70%–80% HNF4A+ cells may be obtained, whereas other he-
patic genes displayed peak expression on days 16 (D16) or 24 (D24) (Figures 3A and S4A).
During hepatic differentiation, we noted that control-hiPSCs formed polygonal hepatocyte-like cells,
whereas MODY1-hiPSCs did not (Figure S4B). In addition, MODY1 hepatic progenitors expressed signifi-
cantly lower levels of HNF4A and HHEX on D8, leading to reduced expression of HNF1A and hepatoblast
marker AFP on D16, and finally reduced levels of key mature hepatocyte markers APOA2, APOB, APOC1,
APOE, and ALB on D24 as opposed to control cells (Figure 3B). Residual HNF4A protein expressed in the
MODY1 hepatic progenitors appeared to localize largely to the cytoplasm when compared with the con-
trols (Figure S4), mirroring our earlier observations in the HPPs (Figure 1F). These data indicated that
the early HNF4A loss-of-function effects (despite having a WT HNF4A allele) propagated into longer-
term consequences that affected subsequent hepatic differentiation. This is consistent with the effects196 iScience 16, 192–205, June 28, 2019
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Figure 3. MODY1-Mediated HNF4A Haploinsufficiency in Early Foregut Development Affects Subsequent Hepatic and Pancreatic Development
Signatures
(A and B) (A) qPCR analyses showing pattern of hepatic gene expression over a 24-day differentiation in control-hiPSC-derived hepatic cells and (B)
comparison of hepatic gene expression changes between control and MODY1 hepatic cells.
(C and D) (C) qPCR analyses showing pattern of pancreatic b cell gene expression over a 35-day differentiation in control-hPSC-derived pancreatic b-like cells
and (D) comparison of b cell gene expression changes between control and MODY1 pancreatic b-like cells.
Data are represented as meanG SD of n = 3, representative of three independent experiments. *p < 0.05 versus control samples by Student’s t test. See also
Figure S4.of shRNA-mediated knockdown of HNF4A in hPSCs that was reported previously (DeLaForest et al., 2011),
although it is worth noting that a complete knockout of HNF4A in humans does not exist naturally.
We next investigated the impact of MODY1/HNF4A mutation on pancreatic b cell development using a
published protocol for generating pancreatic b-like cells (Pagliuca et al., 2014). In differentiated WT
b-like cells, HNF4A expression increased progressively over 35 days, together with other critical b cell tran-
scripts such as HNF1A, PDX1, and INS (Figure 3C). Again, no difference was detected between the spec-
ification of control and MODY1 iPSCs into definitive endoderm cells, before the rise in HNF4A expression
(Figure S4D). However, in MODY1 b-like cells both HNF4A and HNF1A were significantly downregulated,
although this was not the case for a number of other b cell genes tested at D35 (Figure 3D). Despite some
reduction in INS transcript levels in MODY1-derived b-like cells (Figure 3D), we could detect the expression
of C-peptide in both control- and MODY1-derived b-like cells (Figure S4E). To corroborate the results
observed in the MODY1-HPPs (Figure 1E), we also assessed gene expression changes in the pancreatic
progenitors generated using the 35-day b cell differentiation protocol. We observed that the expression
of PDX1 and other progenitor markers was indeed reduced in the D13 pancreatic progenitors (Figure S4F),
although PDX1 reduction at protein level was not always consistently observed (Figure S4G). We postulate
that the early perturbations may be less apparent later in the differentiation owing to the exogenous stimuli
that drive the differentiation of PDX1- and INS-expressing cells during b cell differentiation. Nonetheless, it
was clear from our multiple differentiated cell models that loss in both HNF4A and HNF1A function in early
hepatic and b cell development may contribute to the impaired tissue function in MODY1.
We then sought to define the molecular impact of HNF4A p.Ile271fs on its downstream targets including
HNF1A, by evaluating the transcriptional potential of WT and mutant HNF4A in our hiPSC-derived hepatic
differentiation models. As both P1- and P2-driven transcripts are present during foregut development
(Figure S2E), the effects of both WT and mutant HNF4A2 and HNF4A8 (longest isoforms representative
of P1- and P2-driven expression, respectively) were evaluated. When expressed in the D8 hepatic progen-
itors, WT HNF4A2 significantly activated HNF1A promoter activity, whereas mutant HNF4A did not elicit
the same effect (Figure 4A). Similarly, in the D16 hepatic progenitors, WT but not mutant HNF4A2 resulted
in activation of the APOB promoter and AFP enhancer (containing a HNF4A-binding motif) (Nakabayashi
et al., 2004) (Figures 4B and 4C). The activation of the AFP enhancer by WT, but not mutant HNF4A2, was
further replicated in HepG2 cells (Figure 4D), an AFP-producing human hepatoma cell line (Kawai et al.,
2001). The lack of activation by mutant HNF4A may be explained in part by the reduced protein expression
levels of mutant HNF4A compared with WT, although both HNF4A2/8 WT and mutants localized to the
nuclei in the overexpression studies (Figures S5A and S5B). In all experiments, WT HNF4A8 exhibited a
weaker transactivation potential when compared with HNF4A2, and in the case of the HNF1A promoter
and AFP enhancer, the effect was only significant in MODY1-derived cells where endogenous HNF4A func-
tion is reduced (Figures 4A and 4C).
We further set out to investigate the regulation of HNF1A by HNF4AWT or mutants in human pancreatic b
cells. As the suspension cell clumps generated from the pancreatic b cell differentiation were less
amenable for in vitro assays unlike monolayer differentiation cultures, we used the human b cell line
EndoC-bH1. Chromatin immunoprecipitation analyses in EndoC-bH1 showed that HNF4A was bound to
the HNF1A promoter (Figure 4E), and subsequent knockdown of HNF4A by 55% resulted in a corre-
sponding reduction in HNF1A promoter activation (Figures 4F and 4G). This effect could be rescued by
WTHNF4A overexpression but notmutant HNF4A (Figure 4G). Overall, we have shown that HNF4A directly
regulates the transcription of key components of developing hepatic and pancreatic b cells, and that the
MODY1/HNF4A mutation (p.Ile271fs) results in the inability to activate target promoters. Our patient-
derived iPSC-basedmodel thus provides an in vitro platform for the interrogation of the underlying disease
mechanisms in the hepatic and b cells.198 iScience 16, 192–205, June 28, 2019
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Figure 4. MODY1/HNF4A Mutation Results in Loss of Ability to Activate Downstream Target Promoters in
Hepatic and Pancreatic b Cells
(A–D) Luciferase assays were performed to evaluate effects of WT or p.Ile271fs (Mut) HNF4A on the (A) HNF1A promoter,
(B) APOB promoter, (C) AFP enhancer activity in hiPSC-derived hepatic cells, or (D) HepG2 cells. For (A–C), data are
represented as mean G SD n = 3, representative of two independent experiments. For (D), data are represented as
mean G SD of n = 12 from three independent experiments. *p < 0.05 versus GFP control in all hiPSC lines by two-way
ANOVA; #p < 0.05 versus GFP control in mutant hiPSC lines only by two-way ANOVA. **p = 0.01 versus GFP control by
Student’s t test.
(E) Chromatin immunoprecipitation qPCR analysis of HNF4A binding onto HNF1A promoter in EndoC-bH1 cells.
(F) Small interfering RNA-mediated knockdown of HNF4A in EndoC-bH1 cells.
(G) Luciferase assay evaluating HNF1A promoter activity upon knockdown of HNF4A and rescue. For (E–G), data are
represented as meanG SD of n = 12 from three to four independent experiments. *p < 0.05 versus IgG/GFP control as
indicated by Student’s t test.
See also Figure S5.
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MODY1 hiPSC-Derived Cells Express Both WT and Mutant HNF4A Transcripts and Do Not
Exhibit Dominant Negativity
Finally, we sought to address the question of why the decrease in total HNF4A levels in MODY1-derived
cells is beyond the expected 2-fold change given the presence of a WT allele in heterozygote carriers.
We first determined the expression of WT and mutant HNF4A (p.Ile271fs) transcripts using a custom-de-
signed allele-specific assay (Figure S5C). As observed across multiple differentiated cell types, both WT
and mutant HNF4A transcripts are expressed in the MODY1-derived cells, confirming heterozygosity at
mRNA level (Figures 5A–5C). The detection of mutant transcripts indicated that there is an absence of com-
plete nonsense-mediated decay (NMD) of the nonsense mutant transcripts (Zhang et al., 2009). Next, we
checked if the MODY1 mutation could result in a dominant negative effect by co-expressing WT and
mutant HNF4A to recapitulate a heterozygous condition. Gene regulatory assays showed that WT
HNF4A was able to activate AFP enhancer activity normally in the presence of mutant protein, suggesting
a lack of dominant negativity (Figure 5D). Given that HNF4A is also known to occupy its own promoter
(Bolotin et al., 2010; Odom et al., 2004), we performed further gene regulatory assays involving both the
HNF4A P1 and P2 promoters and demonstrated that HNF4A can activate both promoters and subse-
quently its own expression in a feedforward manner (Figure 5E). Therefore loss of HNF4A function or
mislocalization may result in failure to undergo autoregulation, accounting for overall reduced HNF4A
expression in MODY1.DISCUSSION
Earlier studies have reported HNF4A nonsense or missense gene mutations leading to either a loss-of-
function or a dominant negative effect (Laine et al., 2000; Lausen et al., 2000; Sladek et al., 1998). The
p.Ile271fs mutation in our study introduces a frameshift and premature stop codon, which could lead to
generation of unstable mRNA that may to some degree be degraded by NMD (Frischmeyer and Dietz,
1999), accounting for the overall lowered HNF4A levels in MODY1-hiPSC-derived cells. However, we did
not observe complete NMD given that mutant transcripts were detectable in our MODY1-derived cells.
At protein level, crystallographic studies have reported that several key residues of the ligand-binding
domain are involved in charge-driven interactions that improve dimerization. Mutations in this region
such as p.Ile271fs may therefore affect the formation of functional homodimers and impair DNA-binding
activity, thereby abolishing transcriptional activity or coactivator recruitment (Eeckhoute et al., 2003b; Ek
et al., 2005; Hani et al., 1998; Stoffel and Duncan, 1997) to affect downstream gene regulation. Our work
conclusively showed that loss of HNF4A-mediated gene regulation due to the p.Ile271fs mutation in a
heterozygous state in MODY1 affected foregut endoderm gene expression signatures.
Our observations on caudal HOX gene upregulation led us to hypothesize that HNF4A typically functions
to suppress ectopic hindgut HOX gene expression to facilitate proper foregut endoderm development,
whereas this suppressive effect is disrupted in cells carrying the p.Ile271fs mutation. Further studies are
required to determine whether HOX gene derepression is indirect, or if HNF4A requires other co-factors
for its repressor function. Future work should also determine whether p.Ile271fs affects the specific inter-
action of HNF4A with ligands or co-factors important for its function. We propose that the impact of
HNF4A haploinsufficiency on the specification of the foregut versus hindgut lineage is cell autonomous
given the well-established function of HNF4A as a transcription factor. Nonetheless, the possibility of
non–cell autonomy cannot be ruled out as previous studies have provided evidence for non-cell-autono-
mous functions of homeobox genes and other early developmental genes (Balbinot et al., 2018; Becker
et al., 2016). Future experiments that involve fluorescent labeling of the WT and mutant MODY1 hiPSCs
followed by differentiation and fluorescence-activated cell sorting analyses may shed light on this.
HNF4A has been reported to be important for rodent hepatocyte development (Li et al., 2000) and is essen-
tial for specifying the early hepatic differentiation program (DeLaForest et al., 2011). However, the impact
of MODY1/HNF4A mutation on hepatic development in humans has not been explored, given the intrac-
tability of human liver tissue. Here, we capitalize on our patient-derived iPSCs and ability to differentiate
them into multiple relevant cell types to model cell-type-specific phenotypes and investigate underlying
disease mechanisms. Our results indicated that the early loss of HNF4A expression in hepatoblasts prop-
agated to long-term consequences on hepatic cell fate, as seen in the reduced expression of ALB and
numerous APO genes. This is consistent with observations that patients with MODY1 with an inactivating
HNF4A mutation exhibit reduced secretion of hepatocyte-specific proteins such as APOs (Lehto et al.,
1999; Pearson et al., 2005; Shih et al., 2000). Nonetheless, these alterations in liver function may not be200 iScience 16, 192–205, June 28, 2019
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Figure 5. MODY1 hiPSC-Derived Cells Express Both WT and Mutant HNF4A Transcripts
(A–C) Allele-specific qPCR analyses in (A) D14 HPPs, (B) D8 hepatoblasts, and (C) D35 b-like cells evaluating both WT and
mutant HNF4A transcripts in MODY1-derived cells. Axes show relative fluorescence units for each allele-specific TaqMan
probe, for a representative differentiation experiment.
(D) Luciferase assays were performed to evaluate effects of WT and mutant HNF4A in combination with AFP enhancer
activity in HepG2 cells.
(E) Luciferase assays were performed to evaluate effects of HNF4A2 and HNF4A8 onHNF4A P1 and P2 promoter activities
in Ad293 cells.
Data are represented as meanG SD of n = 4 independent experiments. **p < 0.01 versus GFP control unless otherwise
indicated by Student’s t test. See also Figure S5.
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clinically significant given the lack of reports on liver deformities or severe liver dysfunction in these pa-
tients. Given the potential redundancy within the complex liver transcription factor network that HNF4A
is involved in (Lau et al., 2018; Odom et al., 2004), there may be redundant mechanisms such as those
involving HNF1A or ONECUT1 in the liver, or other compensatory mechanisms that enable largely normal
liver development in vivo (Ober et al., 2006).
We also confirmed that although both P1- and P2-driven HNF4A are expressed during foregut differenti-
ation, the primary isoform(s) that activates expression of key target genes such as HNF1A and AFP is likely
encoded by the P1 promoter. These results are consistent with previous reports (Eeckhoute et al., 2003a)
that P1-driven isoforms exhibit greater transcriptional potential than their P2-driven counterparts, and we
show that this is the case in both human hepatic cells and b cells.
Besides a liver phenotype, patients with MODY1 are known to exhibit progressive b cell insulin secretory
defects (Herman et al., 1997; Ryffel, 2001). Our studies provide valuable insights relating to the expression
of early pancreatic genes affected byHNF4A haploinsufficiency such asHNF1B, PDX1,GATA4, and RFX6 in
the pancreatic progenitors. Although key developmental genes may be perturbed at the progenitor stage,
the terminally in vitro-differentiated b-like cells were still able to express select b cell markers and C-pep-
tide. This observation is in line with a previous study also involvingMODY1-derived cells (Vethe et al., 2017).
However, the study did not provide data from any of the progenitor stages. In both our study and that by
Vethe et al., the in vitro differentiations do not generate b-like cells that are functionally mature despite the
presence of insulin, therefore the functional capacity of these cells cannot be appropriately elucidated. As
HNF4A haploinsufficiency involves a heterozygous mutation, there could be compensatory effects that
result in a reset of the regulatory network, therefore patients do not have pancreatic agenesis. Nonethe-
less, there is a distinctive decrease in HNF1A expression in our MODY1-derived b-like cells. These findings
are also consistent with the prevailing notion that MODY1/HNF4A is clinically and genetically linked to
MODY3/HNF1A considering that HNF4A directly regulates the expression of HNF1A (Ellard and Col-
clough, 2006; Lausen et al., 2000). Detailed assessment of how the HNF4A-HNF1A cross-regulatory circuit
and downstream transcriptional network is perturbed in both MODY1 and MODY3 may shed further
light on the convergent and divergent role of both genes in governing tissue function, especially in human
b cells.
It is notable that mutations in HNF4A are not only relevant to MODY1 but also have been associated with
the more commonly occurring type 2 diabetes (T2D). Specifically, single nucleotide polymorphisms in both
the P2 and P1 promoter regions and those near or within the HNF4A gene have been linked to T2D suscep-
tibility (Damcott et al., 2004; Ek et al., 2005; Hara et al., 2006; Kooner et al., 2011; Love-Gregory et al., 2004;
Mahajan et al., 2018; Silander et al., 2004; Weedon et al., 2004). Pancreatic islets isolated from donors with
T2D were also found to exhibit reducedHNF4A expression (Gunton et al., 2005). Collectively, we report the
successful establishment of a MODY1 hiPSC model with HNF4A haploinsufficiency that arose from a natu-
rally occurring heterozygous mutation. Our findings highlight MODY1-HNF4A as a developmental disease
that begins in the foregut endoderm and extends to its derivatives—in particular the liver and the pancreas.
Our approach and results will have important implications for the study and understanding of diabetes
pathogenesis in the context of MODY and even T2D.Limitations of the Study
In this study, we have validated our findings across multiple differentiationmodels that can generate known
cell-type-specific markers, as well as established mechanisms in non-iPSC-based cell lines to substantiate
our findings of HNF4A haploinsufficiency. However, there are well-recognized limitations of iPSC-based
disease models that can affect the interpretation of results. First, the differentiation process is heteroge-
neous and therefore a bulk analysis approach may result in data with overall increased variability and
reduced magnitude of effect. To circumvent this, single-cell studies may be used to interrogate cellular
phenotypes at single-cell resolution (Petersen et al., 2017). Second, the use of isogenic controls generated
using genome-editing tools may also help to reduce noise when compared with the use of family controls,
which are still subject to differences in genetic background (Teo et al., 2015a). Next, directed differentiation
protocols rely on the use of a cocktail of small molecules and growth factors to drive the differentiation pro-
cess in vitro. This assumes that patient cells encounter these signals under an in vivo setting to drive tissue
development. Therefore, an in vitro model may not accurately capture disease progression. On the con-
trary, currently available pancreatic b cell differentiation protocols are often unable to generate functional202 iScience 16, 192–205, June 28, 2019
b cells in vitro and require transplantation into mice for in vivo maturation (Hrvatin et al., 2014; Loo et al.,
2018). This hints at yet unknown molecular factors that are required to obtain b cells that can produce and
secrete insulin in response to glucose stimuli. Therefore evaluation of the insulin secretory capacity of the
MODY1-derived cells in the current differentiation model was not possible. Overcoming a number of these
limitations will undoubtedly increase experimental robustness and reproducibility.
METHODS
All methods and can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
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ACKNOWLEDGMENTS
The authors thank Andreas Alvin Purnomo Soetedjo and Chek Mei Bok for experimental assistance and
also thank members of the Teo laboratory for the critical reading of this manuscript. N.H.J.N. is supported
by the National Medical Research Council (NMRC) Open Fund-Young Individual Research Grant (OF-YIRG)
OFYIRG18May. R.N.K. acknowledges support from National Institutes of Health Grant RO1 067536. H.R. is
supported by the Bergen Forskningsstiftelse (BFS), the Western Norway Regional Health Authority, the
Novo Nordisk Foundation, and Diabetesforbundet. L.V. is funded by the ERC advanced grant New-
Chol, the Cambridge University Hospitals National Institute for Health Research Biomedical Research
Centre and the core support grant from the Wellcome Trust and Medical Research Council to the Well-
come–Medical Research Council Cambridge Stem Cell Institute. A.K.K.T. is supported by the Institute of
Molecular and Cell Biology (IMCB), A*STAR, A*STAR JCO Career Development Award (CDA)
15302FG148, NMRC OFYIRG16may014, A*STAR ETPL Gap Funding ETPL/18-GAP005-R20H, Lee Founda-
tion Grant SHTX/LFG/002/2018, Skin Innovation Grant SIG18011, NMRC OF-LCG/DYNAMO, FY2019 Sing-
Health Duke-NUS Surgery Academic Clinical Program Research Support Program Grant, and the Precision
Medicine and Personalised Therapeutics Joint Research Grant 2019.
AUTHOR CONTRIBUTIONS
Conceptualization, A.K.K.T.; Methodology, N.H.J.N., J.B.J., and A.K.K.T.; Formal Analysis, N.H.J.N., J.B.J.,
and A.K.K.T.; Investigation, N.H.J.N., J.B.J., C.S.L., H.H.L., V.G.K., J.K., S.H., and A.K.K.T.; Resources, H.R.,
L.V., S.H., and A.K.K.T.; Writing – Original Draft, A.K.K.T.; Writing – Review & Editing, N.H.J.N., J.B.J.,
R.N.K., H.R., L.V., S.H., and A.K.K.T.; Visualization, N.H.J.N., J.B.J., and A.K.K.T.; Supervision, A.K.K.T.; Proj-
ect Administration, A.K.K.T.; Funding Acquisition, A.K.K.T.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: June 25, 2018
Revised: November 20, 2018
Accepted: May 22, 2019
Published: June 28, 2019REFERENCES
Ameri, J., Stahlberg, A., Pedersen, J., Johansson,
J.K., Johannesson, M.M., Artner, I., and Semb, H.
(2010). FGF2 specifies hESC-derived definitive
endoderm into foregut/midgut cell lineages in a
concentration-dependent manner. StemCells 28,
45–56.
Balbinot, C., Armant, O., Elarouci, N., Marisa,
L., Martin, E., De Clara, E., Onea, A.,
Deschamps, J., Beck, F., Freund, J.N., et al.
(2018). The Cdx2 homeobox gene suppresses
intestinal tumorigenesis through non-cell-
autonomous mechanisms. J. Exp. Med. 215,
911–926.Becker, H., Renner, S., Technau, G.M., and
Berger, C. (2016). Cell-autonomous and non-cell-
autonomous function of hox genes specify
segmental neuroblast identity in the gnathal
region of the embryonic CNS in Drosophila. PLoS
Genet. 12, e1005961.
Boj, S.F., Petrov, D., and Ferrer, J. (2010). Epistasis
of transcriptomes reveals synergism between
transcriptional activators Hnf1a and Hnf4a. PLoS
Genet. 6, e1000970.
Bolotin, E., Liao, H., Chi Ta, T., Yang, C., Hwang-
Verslues, W., Evans, J.R., Jiang, T., and Sladek,F.M. (2010). Integrated approach for the
identification of human hepatocyte nuclear
factor 4a target genes using protein binding
microarrays. Hepatology 51, 642–653.
Byrne, M.M., Sturis, J., Fajans, S.S., Ortiz, F.J.,
Stoltz, A., Stoffel, M., Smith, M.J., Bell, G.I.,
Halter, J.B., and Polonsky, K.S. (1995). Altered
insulin secretory responses to glucose in subjects
with a mutation in the mody1 gene on
chromosome-20. Diabetes 44, 699–704.
Damcott, C.M., Hoppman, N., Ott, S.H., Reinhart,
L.J., Wang, J., Pollin, T.I., O’Connell, J.R.,iScience 16, 192–205, June 28, 2019 203
Mitchell, B.D., and Shuldiner, A.R. (2004).
Polymorphisms in both promoters of hepatocyte
nuclear factor 4-alpha are associated with type 2
diabetes in the Amish. Diabetes 53, 3337–3341.
DeLaForest, A., Nagaoka, M., Si-Tayeb, K., Noto,
F.K., Konopka, G., Battle, M.A., and Duncan, S.A.
(2011). HNF4A is essential for specification of
hepatic progenitors from human pluripotent
stem cells. Development 138, 4143–4153.
Eeckhoute, J., Moerman, E., Bouckenooghe, T.,
Lukoviak, B., Pattou, F., Formstecher, P., Kerr-
Conte, J., Vandewalle, B., and Laine, B. (2003a).
Hepatocyte nuclear factor 4 alpha isoforms
originated from the P1 promoter are expressed in
human pancreatic beta-cells and exhibit stronger
transcriptional potentials than P2 promoter-
driven isoforms. Endocrinology 144, 1686–1694.
Eeckhoute, J., Oxombre, B., Formstecher, P.,
Lefebvre, P., and Laine, B. (2003b). Critical role of
charged residues in helix 7 of the ligand binding
domain in Hepatocyte Nuclear Factor 4a
dimerisation and transcriptional activity. Nucleic
Acids Res. 31, 6640–6650.
Ek, J., Rose, C.S., Jensen, D.P., Glumer, C., Borch-
Johnsen, K., Jorgensen, T., Pedersen, O., and
Hansen, T. (2005). The functional Thr130Ile and
Val255Met polymorphisms of the hepatocyte
nuclear factor-4 alpha (HNF4A): gene
associations with type 2 diabetes or altered beta-
cell function among Danes. J. Clin. Endocrinol.
Metab. 90, 3054–3059.
Ellard, S., and Colclough, K. (2006). Mutations in
the genes encoding the transcription factors
hepatocyte nuclear factor 1 alpha (HNF1A) and 4
alpha (HNF4A) in maturity-onset diabetes of the
young. Hum. Mutat. 27, 854–869.
Frischmeyer, P.A., and Dietz, H.C. (1999).
Nonsense-mediated mRNA decay in health and
disease. Hum. Mol. Genet. 8, 1893–1900.
Gardner, D.S.L., and Tai, E.S. (2012). Clinical
features and treatment ofmaturity onset diabetes
of the young (MODY). Diabetes Metab. Syndr.
Obes. 5, 101–108.
Gunton, J.E., Kulkarni, R.N., Yim, S., Okada, T.,
Hawthorne, W.J., Tseng, Y.-H., Roberson, R.S.,
Ricordi, C., O’Connell, P.J., Gonzalez, F.J., et al.
(2005). Loss of ARNT/HIF1b mediates altered
gene expression and pancreatic-islet dysfunction
in human type 2 diabetes. Cell 122, 337–349.
Gupta, R.K., Vatamaniuk, M.Z., Lee, C.S.,
Flaschen, R.C., Fulmer, J.T., Matschinsky, F.M.,
Duncan, S.A., and Kaestner, K.H. (2005). The
MODY1 gene HNF-4a regulates selected genes
involved in insulin secretion. J. Clin. Invest. 115,
1006–1015.
Hani, E., Suaud, L., Boutin, P., Chevre, J.C.,
Durand, E., Philippi, A., Demenais, F., Vionnet, N.,
Furuta, H., Velho, G., et al. (1998). A missense
mutation in hepatocyte nuclear factor-4 alpha,
resulting in a reduced transactivation activity, in
human late-onset non-insulin-dependent
diabetes mellitus. J. Clin. Invest. 101, 521–526.
Hannan, N.R., Segeritz, C.P., Touboul, T., and
Vallier, L. (2013). Production of hepatocyte-like
cells from human pluripotent stem cells. Nat.
Protoc. 8, 430–437.204 iScience 16, 192–205, June 28, 2019Hara, K., Horikoshi, M., Kitazato, H., Lto, C.,
Noda, M., Ohashi, J., Froguel, P., Tokunaga, K.,
Tobe, K., Nagai, R., et al. (2006). Hepatocyte
nuclear factor-4 alpha P2 promoter haplotypes
are associated with type 2 diabetes in the
Japanese population. Diabetes 55, 1260–1264.
Harries, L.W., Locke, J.M., Shields, B., Hanley,
N.A., Hanley, K.P., Steele, A., Njolstad, P.R.,
Ellard, S., and Hattersley, A.T. (2008). The diabetic
phenotype in HNF4A mutation carriers is
moderated by the expression of HNF4A isoforms
from the P1 promoter during fetal development.
Diabetes 57, 1745–1752.
Herman, W.H., Fajans, S.S., Smith, M.J., Polonsky,
K.S., Bell, G.I., and Halter, J.B. (1997). Diminished
insulin and glucagon secretory responses to
arginine in nondiabetic subjects with a mutation
in the hepatocyte nuclear factor-4alpha/MODY1
gene. Diabetes 46, 1749–1754.
Hrvatin, S., O’Donnell, C.W., Deng, F., Millman,
J.R., Pagliuca, F.W., DiIorio, P., Rezania, A.,
Gifford, D.K., and Melton, D.A. (2014).
Differentiated human stem cells resemble fetal,
not adult, beta cells. Proc. Natl. Acad. Sci. U S A
111, 3038–3043.
Huang, J., Levitsky, L.L., and Rhoads, D.B. (2009).
Novel P2 promoter-derived HNF4a isoforms with
different N-terminus generated by alternate exon
insertion. Exp. Cell Res. 315, 1200–1211.
Jiang, S., Tanaka, T., Iwanari, H., Hotta, H.,
Yamashita, H., Kumakura, J., Watanabe, Y.,
Uchiyama, Y., Aburatani, H., Hamakubo, T., et al.
(2003). Expression and localization of P1
promoter-driven hepatocyte nuclear factor-4a
(HNF4a) isoforms in human and rats. Nucl.
Recept. 1, 1–12.
Kawai, H.F., Kaneko, S., Honda, M., Shirota, Y.,
and Kobayashi, K. (2001). alpha-fetoprotein-
producing hepatoma cell lines share common
expression profiles of genes in various categories
demonstrated by cDNA microarray analysis.
Hepatology 33, 676–691.
Kooner, J.S., Saleheen, D., Sim, X., Sehmi, J.,
Zhang, W., Frossard, P., Been, L.F., Chia, K.S.,
Dimas, A.S., Hassanali, N., et al. (2011). Genome-
wide association study in individuals of South
Asian ancestry identifies six new type 2 diabetes
susceptibility loci. Nat. Genet. 43, 984–989.
Laine, B., Eeckhoute, J., Suaud, L., Briche, I.,
Furuta, H., Bell, G.I., and Formstecher, P. (2000).
Functional properties of the R154X HNF-4alpha
protein generated by a mutation associated with
maturity-onset diabetes of the young, type 1.
FEBS Lett. 479, 41–45.
Lau, H.H., Ng, N.H.J., Loo, L.S.W., Jasmen, J.B.,
and Teo, A.K.K. (2018). Themolecular functions of
hepatocyte nuclear factors - in and beyond the
liver. J. Hepatol. 68, 1033–1048.
Lausen, J., Thomas, H., Lemm, I., Bulman, M.,
Borgschulze, M., Lingott, A., Hattersley, A.T., and
Ryffel, G.U. (2000). Naturally occurring mutations
in the human HNF4alpha gene impair the
function of the transcription factor to a varying
degree. Nucleic Acids Res. 28, 430–437.
Lehto, M., Bitzen, P.O., Isomaa, B., Wipemo, C.,
Wessman, Y., Forsblom, C., Tuomi, T., Taskinen,
M.R., and Groop, L. (1999). Mutation in the HNF-4alpha gene affects insulin secretion and
triglyceride metabolism. Diabetes 48, 423–425.
Li, J., Ning, G., and Duncan, S.A. (2000).
Mammalian hepatocyte differentiation requires
the transcription factor HNF-4a. Genes Dev. 14,
464–474.
Loo, L.S.W., Lau, H.H., Jasmen, J.B., Lim, C.S.,
and Teo, A.K.K. (2018). An arduous journey from
human pluripotent stem cells to functional
pancreatic beta cells. Diabetes Obes. Metab. 20,
3–13.
Love-Gregory, L.D., Wasson, J., Ma, J., Jin, C.H.,
Glaser, B., Suarez, B.K., and Permutt, M.A. (2004).
A common polymorphism in the upstream
promoter region of the hepatocyte nuclear
factor-4 alpha gene on chromosome 20q is
associated with type 2 diabetes and appears to
contribute to the evidence for linkage in an
ashkenazi jewish population. Diabetes 53, 1134–
1140.
Mahajan, A., Wessel, J., Willems, S.M., Zhao, W.,
Robertson, N.R., Chu, A.Y., Gan, W., Kitajima, H.,
Taliun, D., Rayner, N.W., et al. (2018). Refining the
accuracy of validated target identification
through coding variant fine-mapping in type 2
diabetes. Nat. Genet. 50, 559–571.
Miura, A., Yamagata, K., Kakei, M., Hatakeyama,
H., Takahashi, N., Fukui, K., Nammo, T., Yoneda,
K., Inoue, Y., Sladek, F.M., et al. (2006).
Hepatocyte nuclear factor-4alpha is essential for
glucose-stimulated insulin secretion by
pancreatic beta-cells. J. Biol. Chem. 281, 5246–
5257.
Nakabayashi, H., Koyama, Y., Suzuki, H., Li, H.M.,
Sakai, M., Miura, Y., Wong, N.C., and Nishi, S.
(2004). Functional mapping of tissue-specific
elements of the human alpha-fetoprotein gene
enhancer. Biochem. Biophys. Res. Commun. 318,
773–785.
Nammo, T., Yamagata, K., Tanaka, T., Kodama,
T., Sladek, F.M., Fukui, K., Katsube, F., Sato, Y.,
Miyagawa, J., and Shimomura, I. (2008).
Expression of HNF-4alpha (MODY1), HNF-1beta
(MODY5), and HNF-1alpha (MODY3) proteins in
the developing mouse pancreas. Gene Expr.
Patterns 8, 96–106.
Ober, E.A., Verkade, H., Field, H.A., and Stainier,
D.Y. (2006). Mesodermal Wnt2b signalling
positively regulates liver specification. Nature
442, 688–691.
Odom, D.T., Zizlsperger, N., Gordon, D.B., Bell,
G.W., Rinaldi, N.J., Murray, H.L., Volkert, T.L.,
Schreiber, J., Rolfe, P.A., Gifford, D.K., et al.
(2004). Control of pancreas and liver gene
expression by HNF transcription factors. Science
303, 1378–1381.
Pagliuca, F.W., Millman, J.R., Gurtler, M., Segel,
M., Van Dervort, A., Ryu, J.H., Peterson, Q.P.,
Greiner, D., and Melton, D.A. (2014). Generation
of functional human pancreatic beta cells in vitro.
Cell 159, 428–439.
Pearson, E.R., Pruhova, S., Tack, C.J., Johansen,
A., Castleden, H.A.J., Lumb, P.J., Wierzbicki, A.S.,
Clark, P.M., Lebl, J., Pedersen, O., et al. (2005).
Molecular genetics and phenotypic
characteristics of MODY caused by hepatocyte
nuclear factor 4a mutations in a large European
collection. Diabetologia 48, 878–885.
Petersen, M.B.K., Azad, A., Ingvorsen, C.,
Hess, K., Hansson, M., Grapin-Botton, A., and
Honore, C. (2017). Single-cell gene expression
analysis of a human ESC model of pancreatic
endocrine development reveals different
paths to beta-cell differentiation. Stem Cell
Reports 9, 1246–1261.
Ryffel, G.U. (2001). Mutations in the human genes
encoding the transcription factors of the
hepatocyte nuclear factor (HNF)1 and HNF4
families: functional and pathological
consequences. J. Mol. Endocrinol. 27, 11–29.
Shih, D.Q., Dansky, H.M., Fleisher, M., Assmann,
G., Fajans, S.S., and Stoffel, M. (2000). Genotype/
phenotype relationships in HNF-4alpha/MODY1:
haploinsufficiency is associated with reduced
apolipoprotein (AII), apolipoprotein (CIII),
lipoprotein(a), and triglyceride levels. Diabetes
49, 832–837.
Silander, K., Mohlke, K.L., Scott, L.J., Peck, E.C.,
Hollstein, P., Skol, A.D., Jackson, A.U., Deloukas,
P., Hunt, S., Stavrides, G., et al. (2004). Genetic
variation near the hepatocyte nuclear factor-4
alpha gene predicts susceptibility to type 2
diabetes. Diabetes 53, 1141–1149.
Sladek, F.M., Dallas-Yang, Q., and Nepomuceno,
L. (1998). MODY1 mutation Q268X in hepatocyte
nuclear factor 4alpha allows for dimerization in
solution but causes abnormal subcellular
localization. Diabetes 47, 985–990.
Sladek, F.M., Zhong, W.M., Lai, E., and Darnell,
J.E., Jr. (1990). Liver-enriched transcription factorHNF-4 is a novel member of the steroid hormone
receptor superfamily. Genes Dev. 4, 2353–2365.
Stoffel, M., and Duncan, S.A. (1997). Thematurity-
onset diabetes of the young (MODY1)
transcription factor HNF4 alpha regulates
expression of genes required for glucose
transport and metabolism. Proc. Natl. Acad. Sci.
U S A 94, 13209–13214.
Tanaka, T., Jiang, S., Hotta, H., Takano, K.,
Iwanari, H., Sumi, K., Daigo, K., Ohashi, R., Sugai,
M., Ikegame, C., et al. (2006). Dysregulated
expression of P1 and P2 promoter-driven
hepatocyte nuclear factor-4a in the pathogenesis
of human cancer. J. Pathol. 208, 662–672.
Teo, A.K., Gupta, M.K., Doria, A., and Kulkarni,
R.N. (2015a). Dissecting diabetes/metabolic
disease mechanisms using pluripotent stem cells
and genome editing tools. Mol. Metab. 4,
593–604.
Teo, A.K., Lau, H.H., Valdez, I.A., Dirice, E., Tjora,
E., Raeder, H., and Kulkarni, R.N. (2016). Early
developmental perturbations in a human stem
cell model of MODY5/HNF1B pancreatic
hypoplasia. Stem Cell Reports 6, 357–367.
Teo, A.K., Tsuneyoshi, N., Hoon, S., Tan, E.K.,
Stanton, L.W., Wright, C.V., and Dunn, N.R.
(2015b). PDX1 binds and represses hepatic genes
to ensure robust pancreatic commitment in
differentiating human embryonic stem cells. Stem
Cell Reports 4, 578–590.
Teo, A.K., Wagers, A.J., and Kulkarni, R.N.
(2013a). New opportunities: harnessing inducedpluripotency for discovery in diabetes and
metabolism. Cell Metab. 18, 775–791.
Teo, A.K., Windmueller, R., Johansson, B.B.,
Dirice, E., Njolstad, P.R., Tjora, E., Raeder, H., and
Kulkarni, R.N. (2013b). Derivation of human
induced pluripotent stem cells from patients with
maturity onset diabetes of the young. J. Biol.
Chem. 288, 5353–5356.
Vethe, H., Bjorlykke, Y., Ghila, L.M., Paulo,
J.A., Scholz, H., Gygi, S.P., Chera, S., and
Raeder, H. (2017). Probing the missing
mature beta-cell proteomic landscape in
differentiating patient iPSC-derived cells. Sci.
Rep. 7, 4780.
Weedon, M.N., Owen, K.R., Shields, B., Hitman,
G., Walker, M., McCarthy, M.I., Love-Gregory,
L.D., Permutt, M.A., Hattersley, A.T., and Frayling,
T.M. (2004). Common variants of the hepatocyte
nuclear factor-4 alpha P2 promoter are
associated with type 2 diabetes in the UK
population. Diabetes 53, 3002–3006.
Yamagata, K., Furuta, H., Oda, N., Kaisaki, P.J.,
Menzel, S., Cox, N.J., Fajans, S.S., Signorini, S.,
Stoffel, M., and Bell, G.I. (1996). Mutations in the
hepatocyte nuclear factor-4[alpha] gene in
maturity-onset diabetes of the young (MODY1).
Nature 384, 458–460.
Zhang, Z., Xin, D., Wang, P., Zhou, L., Hu, L.,
Kong, X., and Hurst, L.D. (2009). Noisy splicing,
more than expression regulation, explains why
some exons are subject to nonsense-mediated
mRNA decay. BMC Biol. 7, 23.iScience 16, 192–205, June 28, 2019 205
ISCI, Volume 16Supplemental InformationHNF4A Haploinsufﬁciency in MODY1
Abrogates Liver and Pancreas Differentiation
from Patient-Derived Induced Pluripotent Stem Cells
Natasha Hui Jin Ng, Joanita Binte Jasmen, Chang Siang Lim, Hwee Hui Lau, Vidhya
Gomathi Krishnan, Juned Kadiwala, Rohit N. Kulkarni, Helge Ræder, Ludovic
Vallier, Shawn Hoon, and Adrian Kee Keong Teo
A 
iN904-7B 
iN904-7C 
iN904-13B 
iN904-13A 
Wild type HNF4A  
iN904-7A 
iN904-1A 
iN904-1B 
iN904-1C 
iN904-2 
p.Ile271fs 
Mutant HNF4A 
B 
OCT4 
SOX2 
NANOG 
TRA-1-60 
DAPI 
DAPI 
DAPI 
DAPI 
OCT4 
SOX2 
NANOG 
TRA-1-60 
DAPI 
DAPI 
DAPI 
DAPI 
OCT4 
SOX2 
NANOG 
TRA-1-60 
DAPI 
DAPI 
DAPI 
DAPI 
OCT4 
SOX2 
NANOG 
TRA-1-60 
DAPI 
DAPI 
DAPI 
DAPI 
iN904-13 
Control Mutant 
iN904-7 iN904-2 iN904-1 
SOX17 
GATA4 
EOMES 
T 
SOX1 
NESTIN 
SOX17 
GATA4 
EOMES 
T 
SOX1 
NESTIN 
SOX17 
GATA4 
EOMES 
T 
SOX1 
NESTIN 
SOX17 
GATA4 
EOMES 
T 
SOX1 
NESTIN DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
iN904-13 
Control Mutant 
iN904-7 iN904-2 iN904-1 
C 
Figure S1, related to Figure 1. Characterization of MODY1-hiPSCs. (A) DNA sequencing to verify absence or 
presence of HNF4A p.Ile271fs mutation in control- and MODY1-hiPSCs. Control- and MODY1-hiPSCs (B) express 
pluripotency markers and (C) can give rise to cell types making up the three germ layers. Scale bars: 400 µm. 
Supplemental Figure S1: Ng et al. 
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Figure S2, related to Figure 2. Characterization of the differentiation of iPSCs into D14 
HPPs.  
(A) ~70% of control-hPSC-derived cells are HNF4A+ based on FACS analysis. (B) Co-
expression of definitive endoderm markers SOX17 (Green, R&D AF1924) and CXCR4 (Red, 
BD 555976) was determined at day 3 of differentiation. (C) No obvious morphological 
differences were observed between control- and MODY1-HPPs after 14 days of 
differentiation. (D) Western blot analysis using an antibody against the HNF4A C-terminal 
epitope (that recognizes full-length but not C-terminally-truncated protein) shows markedly 
reduced levels of HNF4A WT protein in MODY1-HPPs. (E) Both HNF4A P1 and P2 
promoter-driven transcripts are expressed by isoform-specific qPCR analysis. Data are 
represented as mean  SD of n=3, representative of 3 independent experiments. (F) 
Expression of pancreatic progenitor markers PDX1 (R&D AF2419) and GATA4 (Thermo 
Fisher 6H10) was downregulated in MODY1-HPPs compared to controls. The percentage of 
PDX1- or GATA4-positive cells were quantified from at least 3 different images, each with 
189-594 cells counted. Data are represented as mean ± SD of n=3. *p < 0.05 versus controls 
as indicated by Student’s t test. Scale bars: 100 μm. 
1
E
-1
3
1
E
-1
2
1
E
-1
1
1
E
-1
0
1
E
-0
9
1
E
-0
8
1
E
-0
7
1
E
-0
6
Regulation of biological quality
Response to wounding
Response to external stimulus
Response to chemical stimulus
Response to inorganic substance
Regulation of hormone levels
Steroid metabolic process
Organ development
Response to stress
Cholesterol transport
Sterol transport
Regulation of multicellular organismal process
Hormone metabolic process
Anatomical structure development
Lipid localization
P value 
G
O
 t
e
rm
 c
a
te
g
o
ry
 –
  
B
io
lo
g
ic
a
l 
P
ro
c
e
s
s
 
Downregulated in MODY1 vs control 
A 
Supplemental Figure S3: Ng et al. 
1
E
-1
2
1
E
-1
1
1
E
-1
0
1
E
-0
9
1
E
-0
8
1
E
-0
7
1
E
-0
6
1
E
-0
5
Sequence-specific DNA binding
Transcription factor activity
Ion channel activity
Calcium ion binding
Gated channel activity
Substrate specific channel activity
Channel activity
Passive transmembrane transporter activity
Transmembrane receptor protein tyrosine kinase…
Voltage-gated cation channel activity
Ion transmembrane transporter activity
Cation channel activity
Metal ion transmembrane transporter activity
Alkali metal ion binding
Voltage-gated channel activity
P value 
G
O
 t
e
rm
 c
a
te
g
o
ry
 –
  
M
o
le
c
u
la
r 
F
u
n
c
ti
o
n
 
Upregulated in MODY1 vs control 
1
E
-0
6
1
E
-0
5
1
E
-0
4
1
E
-0
3
Enzyme inhibitor activity
Steroid binding
Calcium ion binding
Lipid binding
Receptor binding
Carboxylic acid binding
Lipase inhibitor activity
Enzyme regulator activity
Lipoprotein binding
Cholesterol binding
Endopeptidase inhibitor activity
Phosphatidylcholine-sterol O-acyltransferase…
Sterol binding
Cell surface binding
Peptidase inhibitor activity
P value 
G
O
 t
e
rm
 c
a
te
g
o
ry
 –
  
M
o
le
c
u
la
r 
F
u
n
c
ti
o
n
 
Downregulated in MODY1 vs control 
1
E
-3
2
1
E
-3
0
1
E
-2
8
1
E
-2
6
1
E
-2
4
1
E
-2
2
1
E
-2
0
1
E
-1
8
1
E
-1
6
1
E
-1
4
1
E
-1
2
System development
Multicellular organismal development
Anatomical structure development
Nervous system development
Developmental process
Multicellular organismal process
Organ development
Transmission of nerve impulse
Cell adhesion
Biological adhesion
Cell-cell signaling
Neuron differentiation
Pattern specification process
Anatomical structure morphogenesis
Central nervous system development
P value 
G
O
 t
e
rm
 c
a
te
g
o
ry
 –
  
B
io
lo
g
ic
a
l 
P
ro
c
e
s
s
 
Upregulated in MODY1 vs control 
B 
0
0.5
1
1.5
2
2.5
HNF4A 
0
1
2
3
4
CDX2 
0
2
4
6
8
HOXA10 
0
2
4
6
HOXA11 
0
2
4
6
8
HOXA13 
0
0.5
1
1.5
2
2.5
HOXC10 
0
1
2
3
4
5
HOXC11 
0
1
2
3
4
HOXC12 
0
0.5
1
1.5
2
2.5
HOXD12 
0
1
2
3
4
HOXD13 
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 (
n
o
rm
a
li
z
e
d
 t
o
 5
0
 n
g
/m
l 
F
G
F
2
) 
 * 
P=0.05 * 
* 
* 
P=0.07 
0
1
2
3
HOXD11 
* 
FGF2 dose (ng/ml) 
D 
iN
9
0
4
-1
 
iN
9
0
4
-2
 
iN
9
0
4
-7
 
iN
9
0
4
-1
3
 
C
o
n
tr
o
l 
M
u
ta
n
t 
D14 hepato-pancreatic progenitors 
HOXC10 HOXC12 Merge 
C 
Figure S3, related to Figure 2 and Table S1. Gene ontology analyses of global 
transcriptional changes induced by the HNF4A (p.Ile271fs) mutation in MODY1-
HPPs.  
(A) Downregulated genes were involved in biological processes related to steroid 
metabolism and sterol transport, and molecular functions related to enzyme inhibitor 
activity, lipoprotein and sterol binding. (B) Upregulated genes were important for 
developmental processes and molecular functions related to DNA binding and channel 
activity. (C) Expression of representative hindgut markers HOXC10 and HOXC12 were 
evaluated by immunofluorescent confocal microscopy in D14 HPPs. Blue: DAPI, Green: 
HOXC10, Red: HOXC12. Scale bar: 50 µm. (D) High dose of FGF2 treatment increases 
the expression of caudal HOX genes. Data are represented as mean  SD of n=3, 
representative of 3 independent experiments. *P<0.05 versus 50 ng/ml FGF2 (F50) 
samples by Student’s t-test.  
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Figure S4, related to Figure 3. Characterization of hiPSC-derived hepatic and 
pancreatic cells.  
(A) FACS analysis using HNF4A antibodies targeting the N- or C-terminal regions showing 
that 70 – 80% of control-hPSC-derived hepatic progenitors are HNF4A+ at D8. (B) Brightfield 
images showing that hepatocyte-like cells derived from MODY1-hiPSCs lack a polygonal 
morphology after 24 days of differentiation. Scale bar: 100 µm. (C) Immunofluorescent 
confocal images showing that HNF4A protein is predominantly localized to the nuclei in 
control D8 hepatic progenitors but is largely sequestered in the cytoplasm of MODY1 
hepatic progenitors, based on antibodies targeting the N- or C-terminal regions of HNF4A. 
Blue: DAPI, Green: HNF4A, Scale bars: 50 µm. Confocal images were acquired using 
similar scan settings across samples. (D) FACS analysis showed co-expression of definitive 
endoderm (DE) markers SOX17-PE (R&D IC19241P) and CXCR4-APC (BD 555976) 
indicated as ‘double+’, and expression of CXCR4 alone (‘CXCR4+ only’) in control- and 
MODY1-derived cells after 5 days of differentiation in suspension cultures, using the β cell 
differentiation protocol adapted from Pagliuca et al. Data obtained from one experiment. (E) 
Immunofluorescence staining revealed expression of C-peptide (Green, DSHB GN-ID4) in 
both control- and MODY1-derived day 35 β-like cells. Blue: DAPI; scale bar: 50 µm. (F) 
QPCR analyses of D13 pancreatic progenitors generated using the β cell differentiation 
protocol were used to compare gene expression changes between control- and MODY1-
derived cells. Data are represented as mean  SD of n=3, representative of up to 3 
independent experiments. *P<0.05 vs controls by Student’s t-test. (G) FACS analysis 
showed expression of PDX1 (Abcam ab47308) in Day 13 pancreatic progenitors obtained 
using the β cell differentiation protocol. Data are represented as mean  SD of n=2 
independent experiments.  
Supplemental Figure S5: Ng et al. 
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Figure S5, related to Figures 4 and 5. Validation of HNF4A WT and mutant 
overexpression.  
Transient overexpression of WT and mutant (Mut) HNF4A2 and HNF4A8 constructs (N-
terminal FLAG-tagged) are validated by (A) immunostaining in hiPSC-derived D16 hepatic 
progenitors and (B) western blot analysis in Ad293 cells. Blue: DAPI, Red: FLAG-tagged 
HNF4A, Scale bar: 50 µm. (C) Allele-specific qPCR analyses of mRNA from Ad293 
transfected with HNF4A2 or HNF4A8 WT and/or mutant constructs, in triplicates, showed 
clear segregation among the genotypes. Axes show relative fluorescence units for each 
allele-specific TaqMan probe. 
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Table S1 (Excel table, related to Figures 2 and S3). Expression values (RPKM) 
of hiPSC-derived HPPs at D14 from RNA-Seq data. The first 2 columns indicate 
the gene ID and official gene symbol for all protein-coding genes in the dataset. 
FPKM values are shown for control-hiPSC-derived cells (13A, 13B, 7A, 7B, 7C) and 
MODY1-hiPSC-derived cells (2, 1A, 1B, 1C).  
  
 
 
Table S2 (Related to Methods, Figures 1, 2 and 3). Quantitative real-time PCR 
primers used in this study. 
Gene 
Accession 
Number 
Forward Primer (5' to 3') Reverse Primer (5' to 3') 
ABCC8 NM_001287174.1 GGAGCAGCAGCCTTCCTGACA TGCGAAGCATAGGCCACGGG 
ACTIN NM_001101.3 TTGCCGATCCGCCGCCCGTC CCCATGCCCACCATCACGCCCTGG 
AFP NM_001134.2 TGCTTCCAAACAAAGGCAGCAACAG TGTACATGGGCCACATCCAGGAC 
ALB NM_000477.6 CCTGCCTGTTGCCAAAGCTCGAT TGGCTCAGGCGAGCTACTGC 
APOA2 NM_001643.1 AGCCTTGAAGGAGCTTTGGTTCGG ACTGGGTGGCAGGCTGTGTTC 
APOB NM_000384.2 CCTGGGGCAGTGTGATCGCT TGACAAGGGGCGGGTCATGC 
APOC1 NM_001645.4 TCCTGTCGCTCCCGGTCCTG GAAAACCACTCCCGCATCTTGGC 
APOE NM_001302688.1 CCAGGAGCCGGTGAGAAGCG TGTGATTGGCCAGTCTGGAGGC 
CDX2 NM_001265.4 CGGCAGCCAAGTGAAAACCAGG TCGGCTTTCCTCCGGATGGTG 
CYP3A4 NM_017460.5 CCCAGCAAAGAGCAACACAGAGC CAGAGGTGTGGGCCCTGGAAT 
GATA4 NM_001308093.1 GCAGAGAGTGTGTCAACTGTGGGG TGGGGACCCCGTGGAGCTT 
HHEX NM_002729.4 ACACGCACGCCCTGCTCCGC TGGCCAGACGCTTCCTCTCGGGC 
HLXB9 NM_005515.3 GCGTCCACCGCGGGCATGATCC AAGCGCTTGGGCCGCGACAGG 
HNF1A NM_001306179.1  CTTCTGCAGGAGGACCCGTGGCGT GGCGGCCCGCTTCTGCGTCT 
HNF1B NM_000458.3  GGGGCCCGCGTCCCAGCAAA GGCCGTGGGCTTTGGAGGGGG 
HNF4Α 
NM_000457.4, 
NM_175914.4 
GGACGACCAGGTGGCCCTGCTCAGA GCTCCGGGCAGTGCCGAGGGA 
HNF4Α 
(P1) 
NM_000457.4 GTGTTGACGATGGGCAATGACACG CATGCCAGCCCGGAAGCATT 
HNF4Α 
(P2) 
NM_175914.4 CAGTGGAGAGTTCTTACGACACG CTTCTTCGCCCGAATGTCGC 
HOXA10 NM_018951.3 TCCCTGGGCAATTCCAAAGGTGAAA AGGTGGACGCTGCGGCTAAT 
HOXA11 NM_005523.5 TTCCGGCCACACTGAGGACAAG GTTGAGCATGCGGGACAGTTGC 
HOXA13 NM_000522.4 CACTCTGCCCGACGTGGTCTC ACCTTGGTATAAGGCACGCGCT 
HOXC10 NM_017409.3 CCTCGGATAACGAAGCGAAAGAGGA TCTTGCTAATCTCCAGGCGGCG 
HOXC11 NM_014212.3 CGCAGATTTCGGCGAGCGAG TGGTGCCACTTGCCGGATGG 
HOXC12 NM_173860.1 GGGGCCGCTGGTAAACATCCA GGCGTGGGTAGGACAGCGAA 
HOXD11 NM_021192.2 ATGCTCAACCTCACTGACCGGC GGCGCTTCCTGGAGCTCTCAAA 
HOXD12 NM_021193.3 AGCGGAAACCCTACACGAAGCA TGACTTGCTGGTCGCTGAGGTTC 
HOXD13 NM_000523.3 GCTACCACTTCGGCAACGGCTAC GGCACGTGCTGGTAAGGGCTC 
INS NM_000207.2 CCTGCAGGTGGGGCAGGTGGAGC CGGGTGTGGGGCTGCCTGCG 
KCNJ11 NM_000525.3  AGTGGGACCCAGGTGGAGGT GTGGCCTAGGGCCTCACTGC 
MAFA NM_201589.3 GCCCGCTGGCCATCGAGTACGTCA GAGGACAGCGAGCCTGGCGGC 
NKX6.1 NM_006168.2 ACGCACGCCTGGCCTGTACCCC CCCTCTCGGGCCCCGCCAAGTA 
PDX1 NM_000209.3  CCTTCCCGGAGGGAGCCGAGCC GTAGGCCGTGCGCGTCCGCT 
RFX6 NM_173560.3 GCGGCTTGGAACAAGAGGCCA ACGAGTGAAGCCACCCTCATTCTTT 
SOX9 NM_000346.3 ACCAGCCGCGGCGGAGGAAGT GGGATTGCCCCGAGTGCTCGCC 
 
 
 
 
TRANSPARENT METHODS 
 
Generation of hiPSCs 
5 x 105 human fibroblast cells were seeded on a 6-well plate prior to transduction. 
After 24 hours, cells were replenished with medium containing non-integrative 
Sendai reprogramming vectors (polycistronic Klf4–Oct3/4–Sox2, L-Myc, and Klf4) 
according to the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Scientific). 
All experiments with hiPSCs were approved by the Regional Committee of Medical 
and Health Research Ethics (REK 2010/2295), and all methods were performed in 
accordance with the Helsinki Declaration. 
Human PSC culture and differentiation 
HiPSCs generated from human fibroblast cells and H9 cells were at cultured at 37°C 
with 5% CO2 in DMEM/F-12 with 15 mM HEPES (STEMCELL Technologies), 20% 
KnockOut™ serum replacement (KOSR), L-glutamine, NEAA (Life Technologies) 
and supplemented with 10 ng/ml FGF2 (Miltenyi Biotec). HiPSCs were seeded on 
irradiated CF-1 mouse embryonic fibroblasts (MEFs) and hiPSC media was replaced 
every 24 hours.  
HiPSCs or H9 cells were differentiated into HPPs as described previously (Teo et al., 
2012), with some modifications. Briefly, cells were incubated with Dispase 
(STEMCELL Technologies) and Collagenase IV (Life Technologies) and collected by 
mechanical scraping. MEFs were removed by passing the suspension through a 70 
µm cell strainer. Plated cells were differentiated 2 days later in RPMI-1640/2% B-27 
(no vitamin A; serum-free chemically-defined medium) supplemented with 100 ng/ml 
Activin A (R&D Systems), 3 μM CHIR99021 (Tocris) and 10 μM LY294002 (LC 
 
 
Labs). On day 3, differentiation medium containing 50 ng/ml Activin A was added. 
On day 5, differentiation medium containing 50 ng/ml FGF2 (Miltenyi Biotec), 3 μM 
all-trans-retinoic acid (RA) (WAKO), and 10 mM nicotinamide (Sigma) was added, 
followed by subsequent media changes and addition of 20 μM DAPT (Abcam) on 
days 10 and 12. 
HiPSCs and H9 cells were differentiated into hepatocyte-like cells as described 
previously (Hannan et al., 2013), with some modifications. The basal differentiation 
media used was the same as that for the HPP differentiation protocol described 
above during the first 9 days. The same supplements were also used for the first 4 
days of differentiation. On day 5, differentiation medium containing 50 ng/ml Activin 
A was added. From days 6-9, differentiation media supplemented with 20 ng/ml 
BMP4 (Miltenyi Biotec) and 10 ng/ml FGF10 (Miltenyi Biotec) was added and 
replaced daily. From days 10-24, the HCM Bulletkit (Lonza) differentiation media 
supplemented with 30 ng/ml Oncostatin M (Miltenyi Biotec) and 50 ng/ml HGF 
(Miltenyi Biotec) was added and replaced every other day. 
HiPSCs and H9 cells were differentiated into β-like cells as described previously 
(Pagliuca et al., 2014), with some modifications. Cells were dissociated using 
Dispase (STEMCELL Technologies Inc) and Collagenase IV (Life Technologies), 
followed by mechanical scraping. MEFs were removed by passing the suspension 
through a 40 µm cell strainer. TrypLE Express (Life Technologies) was added for 
further dissociation into single cells. 1 x 106 single cells in mTeSR1 (STEMCELL 
Technologies Inc) containing 10 µM of Rho-Kinase Inhibitor (Y27632) (STEMCELL 
Technologies Inc) were seeded into each well of a Corning® CoStar® ultra-Low 
attachment 6-well plate. After 24 hours, media was replaced with mTeSR1 without 
 
 
Y27632 and cells were cultured for another 48h before initiation of differentiation 
(Pagliuca et al., 2014).  
In general, 1–3 independent hiPSC lines per subject were used in experiments, with 
biological triplicates analysed for each line. Experiments were repeated at least 
thrice. 
All hPSC lines used were tested mycoplasma-negative. 
FGF2 dose-response treatments 
H9 cells were differentiated into day 5 cells following the HPP differentiation protocol 
as described above. On day 5 onwards, cells were treated with differentiation 
medium containing increasing doses of FGF2 (Miltenyi Biotec) – 50 ng/ml, 100 
ng/ml, 200 ng/ml, 300 ng/ml till day 14 before being harvested for analysis (Ameri et 
al., 2010). 
Clonal cell line culture 
HepG2 cells were purchased from ATCC (HB-8065) and cultured in DMEM/Low 
glucose (Hyclone) with 10% heat-inactivated FBS (Life Technologies) and 1% NEAA 
(Life Technologies). EndoC-βH1 cells (Ravassard et al., 2011) were purchased from 
Univercell Biosolutions and cultured in DMEM/Low glucose (Life Technologies) 
supplemented with BSA (Sigma Aldrich), penicillin/streptomycin, 2 mM L-glutamine, 
50 µM 2-mercaptoethanol, 10 mM nicotinamide (Sigma Aldrich), 5.5 µg/ml transferrin 
(Sigma Aldrich) and 6.7 ng/ml sodium selenite (Sigma Aldrich) on plates coated with 
2 µg/ml fibronectin (Sigma Aldrich) and 1% ECM (Sigma Aldrich). Ad293 cells were 
cultured in DMEM/High glucose (Hyclone) with 10% heat-inactivated FBS (Life 
Technologies) and 1% NEAA (Life Technologies). 
 
 
All cell lines used were tested mycoplasma-negative. 
Immunofluorescence staining 
Cell clumps were collected at the end of the differentiation and cryo-embedded in 
tissue freezing medium (Leica Biosystems). Cryo-embedded cells were sectioned 
and mounted onto glass slides. Sectioning was performed by the Advanced 
Molecular Pathology Laboratory (AMPL), A*STAR and stored at -80 °C. Cell sections 
or cells in monolayer culture were fixed with 4% paraformaldehyde for 20 minutes, 
permeabilised with 0.1% Triton X-100 in DPBS, then blocked with 5% donkey serum 
or 5% bovine serum albumin in DPBS containing 0.1% Triton X-100, before 
overnight incubation with primary antibodies at 4oC. Primary antibodies used are for 
the detection of HNF4A (C-terminal epitope, Santa Cruz, sc-6556), HNF4A (N-
terminal epitope, Abcam, ab181604), FLAG tag (Sigma Aldrich, F1804), HOXC10 
(Abcam, ab153904), HOXC12 (Life Technologies, MA5-19125), SOX17 (R&D, 
AF1924), CXCR4 (BD Biosciences, 555976), PDX1 (R&D, AF2419), GATA4 
(Thermo Fisher Scientific, MA5-15532) and C-peptide (DSHB, GN-ID4). Secondary 
antibody incubation was carried out followed by staining with DAPI. The secondary 
antibodies used were Alexa Fluor® 488 (Invitrogen, A11055), Alexa Fluor ® 488 
(Invitrogen, 21202), Alexa Fluor® 594 (Invitrogen, A21203) or Alexa Fluor® 488 
(Invitrogen, A21270). Brightfield images were acquired with the Axiovert 200M 
inverted microscope using the Axiovision LE software. Confocal images were 
acquired with the Olympus FV1000 inverted confocal microscope using the Olympus 
Fluoview v3.1 software. 
 
 
 
 
Fluorescence-activated cell sorting (FACS) 
Cells were harvested by mechanical scraping and dissociated into single cells 
following incubation with 0.25% Trypsin/EDTA at 37°C and passed through a 40 µm 
cell strainer. Cell clumps were dissociated into single cells using TrypLE Express 
(Life Technologies) at 37°C and passed through a 40 µm cell strainer. Single cells 
were fixed with 4% paraformaldehyde on ice for 1 hour, then blocked in FACS buffer 
(5% FBS in DPBS) containing 0.1% Triton X-100 on ice for 1 hour, followed by 
incubation with primary antibodies for 1 hour at 4°C. Primary antibodies used are for 
the detection of HNF4A (C-terminal epitope, Santa Cruz, sc-6556), HNF4A (N-
terminal epitope, Abcam, ab181604), SOX17-PE (R&D, IC19241P), CXCR4-APC 
(BD Biosciences, 555976), PDX1 (Abcam, ab47308) and INS (Abcam, ab7842). 
Cells were washed with FACS buffer containing 0.1% Triton X-100 cells and 
incubated with secondary antibodies in the dark for 1 hour at 4°C. The secondary 
antibodies used were Alexa Fluor® 488 (Invitrogen, A11055), Alexa Fluor ® 488 
(Invitrogen, 21202) or Alexa Fluor® 594 (Invitrogen, A11076). Finally, cells were 
washed in FACS buffer, resuspended in DPBS and analysed with the BDTM LSR II 
Flow Cytometer. Data analysis was performed using the FlowJo 7.0 software. 
RNA extraction, reverse transcription and quantitative PCR 
PrepEase RNA Spin Kit (Affymetrix) was used to extract total RNA from 
differentiated hiPSCs according to the manufacturer’s instructions. To remove 
genomic DNA from the preparation, DNase treatment was carried out for 15 minutes 
at room temperature. Purified RNA was reverse transcribed using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). QPCR was performed on the 
CFX384 Touch™ Real-Time PCR Detection System with iTaq™ Universal 
 
 
SYBR® Green Supermix (Bio-Rad). Reported fold changes are based on relative 
expression values calculated using the 2-ΔΔC(T) method with normalization to actin 
expression for each sample. QPCR primers were custom-designed to span exon-
exon junctions, wherever possible, using Primer-BLAST (NCBI). Sequences of 
primers used are listed in Table S2. 
Immunoblotting 
Cells were harvested by mechanical scraping on ice and lysed in M-PER (Thermo 
Scientific) in the presence of protease and phosphatase inhibitors (Sigma Aldrich). 
Protein lysates were quantified using the BCA Assay (Thermo Scientific), separated 
with sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using 
the Mini-PROTEAN Tetra Cell system (Bio-Rad) and transferred to PVDF 
membranes (Bio-Rad). Primary antibodies against endogenous HNF4A protein (Cell 
Signaling, 3113), FLAG tag (Sigma Aldrich) or actin (Sigma Aldrich) were used, 
followed by HRP-conjugated secondary antibodies (Santa Cruz). Chemiluminescent 
signals were detected using Super Signal West Dura Extended Duration substrate 
(Thermo Scientific). 
Generation of expression constructs 
The pCDH plasmid (System Biosciences) containing the CMV promoter, N-terminal 
FLAG tag coding sequence and ampicillin resistance gene was used as the 
expression vector for HNF4A2 and HNF4Α8. HNF4A2 coding sequence was 
amplified from cDNA obtained from control D14 HPPs using the following primers: 
Forward primer 5’ ATGCGACTCTCCAAAACCCTC 3’; Reverse primer: 5’ 
CTAGATAACTTCCTGCTTGGTGA 3’. HNF4A8 coding sequence was amplified 
 
 
from cDNA obtained from human islets (University of Alberta) using Phusion 
polymerase (Thermo Scientific) and the following primers: Forward primer 5’ 
ATGGTCAGCGTGAACGCG 3’; Reverse primer: 5’ 
CTAGATAACTTCCTGCTTGGTGA 3’. PCR products were inserted into the pCDH 
vector using the Quick Ligation Kit (NEB). The ligated plasmid was used to transform 
STBL3 competent cells (Thermo Fisher Scientific). Inserted sequences were verified 
by DNA sequencing. For site-directed mutagenesis, the following primers were used 
to generate the p.Ile271fs mutation by introducing an additional adenine base into 
the HNF4A coding sequence through a PCR using the Phusion polymerase (Thermo 
Scientific): Forward primer 5’ CTCAAAGCCATCAATCTTCTTTGACC 3’; Reverse 
primer: 5’ GTAGGCATACTCATTGTCATCGATC 3’. The parental strand was 
digested following incubation with Dpn1 (NEB). Introduced mutations were verified 
by DNA sequencing. 
Luciferase reporter assays 
The hHNF1A promoter (-605 to +18) and hAPOB promoter (-664 to +7) were cloned 
into the pGL4.10 vector. The hAFP enhancer region (-4730 to -3666) containing the 
HNF4A binding site was cloned into pGL4.23-Promoter vector. The hHNF4A P1 and 
P2 promoter constructs in the pGL4.10 vector were described previously (Teo et al., 
2016). Cell lines or differentiated hiPSCs were co-transfected with the respective 
promoter construct, pRL-TK renilla vector, and an overexpression vector (Empty 
pCDH or pCDH-HNF4A WT or mutant) using Fugene 6 transfection reagent 
(Promega) or Lipofectamine 2000 (Life Technologies). Cells were transfected in 
triplicate wells and each experiment was independently performed at least twice. For 
HNF4A knockdown in EndoC-βH1 cells, siRNA-mediated RNA interference was 
 
 
carried out using 25 nM non-targeting (D-001810-10) or HNF4A-targeting (J-003406-
09) ON-TARGETplus human siRNA (Dharmacon, GE Healthcare) with 
Lipofectamine RNAiMAX (Life Technologies) for 48 hours before transfection for 
luciferase experiments. Cells were harvested 24-48h after transfection, and 
luciferase activity was measured using the Dual Luciferase Assay System 
(Promega). Firefly luciferase activity was normalized to Renilla luciferase activity for 
each well. 
Chromatin immunoprecipitation (ChIP) 
EndoC-βH1 cells from 2 confluent 10 cm plates were cross-linked with 3.3 mg/ml of 
dimethyl 3,3'-dithiobispropionimidate and 1 mg/ml of 3,3’-dithiodipropionic acid di(N-
hydroxysuccinimide ester) (both Sigma Aldrich) for 30 minutes at room temperature 
and with 1% formaldehyde (Amresco) for 15 minutes. The cross-linking reaction was 
quenched with 0.125 M glycine and cells were first lysed in cell lysis buffer (10 mM 
Tris-HCl pH 8, 10 mM NaCl and 0.2% NP-40) and then in nuclear lysis buffer (50 
mM Tris-HCl pH 8, 10 mM EDTA and 1% SDS) on ice in the presence of protease 
inhibitors on ice. Nuclear lysates were diluted in IP dilution buffer (20 mM Tris-HCl 
pH 8, 2 mM EDTA, 150 mM NaCl, 0.01% SDS and 1% Triton X-100) and sonicated 
for 30s on/45s off for 10 cycles using a Q500 sonicator (QSonica) with microtip 
probes at 30% power. Sonicated samples were pre-cleared using 10 µg rabbit IgG 
(Santa Cruz) and Protein A/G agarose beads. Agarose beads were removed by 
centrifugation and a portion of the supernatant was collected as the input control. 
Samples were divided equally and incubated with 10 µg of HNF4A antibody (Santa 
Cruz, sc-8987) or rabbit IgG overnight at 4°C. The following day, samples were 
incubated with Protein A/G agarose beads and the beads were recovered and 
 
 
washed with IP wash buffer and Tris-EDTA buffer. The immunoprecipitated DNA 
was eluted from the beads using IP elution buffer (100 mM NaHCO3, 1% SDS, 100 
mM DTT). Samples were successively treated with RNaseA, NaCl and Proteinase K. 
DNA was extracted by phenol/chloroform extraction. Finally, qPCR was carried out 
on the input, HNF4A pulldown and IgG samples using SYBR green (Bio-Rad), 
targeting the HNF1A promoter or a control region in GAPDH. QPCR data were 
quantitated using a standard curve based on the input DNA, and normalized against 
GAPDH. Results are expressed as fold change for HNF4A pulldown relative to IgG 
control. 
RNA sequencing and differential expression analysis 
Poly-A mRNA was enriched from 1 µg of total RNA with oligo-dT beads (Invitrogen). 
Up to 100 ng of poly-A mRNA recovered was used to construct multiplexed strand-
specific RNA-seq libraries as per manufacturer’s instruction (NEXTflexTM Rapid 
Directional RNA-SEQ Kit, dUTP-Based, v2). Individual library quality was assessed 
with an Agilent 2100 Bioanalyzer and quantified with a QuBit 2.0 fluorometer before 
pooling for sequencing on a HiSeq 2000 (1 x 101 bp read). The pooled libraries were 
quantified using the KAPA quantification kit (KAPA Biosystems) prior to cluster 
formation. Adapter sequences and low quality bases in Fastq read sequences were 
trimmed using Trimmomatic (v.0.33) (parameters: LEADING:3 TRAILING:3 
SLIDINGWINDOW:4:15 MINLEN:36). The quality filtered Fastq sequence reads 
were then aligned to the human genome (hg19) using Tophat (v.2.0.14) (parameters: 
--no-coverage-search --library-type=fr-firststrand) and annotated with Ensembl gene 
IDs. The resulting bam files were used to generate feature read counts using the 
Python package-based htseq-count of HTSeq (v.0.6.1p1) (parameters: default union-
 
 
counting mode, --stranded=reverse). The read count matrix output from HTSeq was 
used to perform differential expression analysis using the edgeR package (available 
in R (v.3.1.3)) in both ‘classic’ and generalized linear model (glm) modes to contrast 
patient versus control. Procedures described in edgeR documentation were followed 
to calculate P-values, FDR adjusted p-values (q-values) and fold-changes. A false 
discovery rate (FDR) cutoff of 0.05 was used to filter significantly differentially 
expressed genes. These genes with Ensembl IDs were mapped to gene symbols. 
Allele-specific qPCR 
A custom TaqMan® assay (Applied Biosystems) was designed to target the human 
HNF4A mRNA sequence surrounding the p.Ile271fs mutation (Assay ID: 
ANRWJVF). QPCR was performed on the CFX384 Touch™ Real-Time PCR 
Detection System (Bio-Rad) using the TaqMan® SNP Genotyping MasterMix 
(Applied Biosystems), according to the manufacturer’s protocol. An allelic 
discrimination plot was generated on R using relative luciferase units (RFU) from the 
HEX (WT allele) and FAM (Mutant allele) probes. 
Statistical analysis 
Statistical parameters, number of replicates (n) and independent experiments 
conducted are indicated in the figure legends. Data represent mean ± SD. Gene 
expression and ChIP qPCR data were analyzed using two-tailed unpaired Student’s 
t-test. Luciferase data were expressed as normalized relative Firefly/Renilla 
luciferase activity. Mean differences in relative activity were analyzed using two-
tailed paired Student’s t-test for clonal cell line studies, while two-way ANOVA with 
Bonferroni post tests (GraphPad Prism) was used for hiPSC-based studies to 
 
 
analyze differences in relative activity segregated by MODY1 status and 
overexpression condition. Immunofluorescence data was quantified by cell counting 
using ImageJ across at least three representative images per condition. Results 
were considered to be significant at P<0.05. 
Data and software availability 
The accession number for the RNA-Seq data reported in this paper is GEO: 
GSE106335. 
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